Glucagon in MODY (Maturity Onset Diabetes of the Young)

University of Oxford

Status: Completed

Conditions: MODY1; MODY3

Treatments: Other: Omission of gliclazide

Study type: Interventional

Funder types: Other

Identifiers

NCT03246828

12538

Details and patient eligibility

About

The aim of this study is to determine whether fasting and post-prandial glucagon secretion is suppressed by gliclazide in patients with HNF1-/4-alpha MODY. Participants will undergo an oral glucose tolerance test (OGTT) before and after omitting their gliclazide medication for 3 days.

Enrollment: 10 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of HNF1-alpha or HNF4-alpha MODY.
• Currently on gliclazide treatment

Exclusion criteria

• Currently taking any anti-diabetic medication other than gliclazide and metformin
• Oral steroid treatment 30 days prior to the start or at any time during the study period.
• Known malignancy or any other condition or circumstance which, in the opinion of the investigator, would affect the patient's ability to participate in the protocol.
• Felt to be unsuitable to participate in the study in the opinion of the Chief Investigator.
• Currently participating in a clinical trial involving an anti-diabetic medication

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

10 participants in 1 patient group

Omission of gliclazide

Experimental group

Treatment:

Other: Omission of gliclazide